Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and ...
The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired in 2016. But Mylan became the first of a group of potential ...
Advair Diskus, by an average of 50%. GSK's new price cap applies to both of those products and the rest of its asthma and ...
Even though Advair’s main patent expired in 2010 and the patent on the Diskus inhaler expired in 2016, until now no-one has managed to get the FDA to approve a cheaper copy of the drug-device ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretideâ„¢ or Advair ®) is ... twice daily from a Diskusâ„¢ inhaler for a 4-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback